Alkem Laboratories Ltd

Alkem Laboratories Ltd has announced the initiation of a forensic audit following an alleged misappropriation of funds by a former employee. The Audit Committee approved the appointment of Grant Thornton Bharat LLP to conduct the audit. The investigation aims to examine the facts and circumstances surrounding the incident, determine the root cause, and recommend corrective measures. The audit will focus on reviewing procurement by the former employee and investigating suspected irregularities in certain transactions. A copy of this disclosure will be made available on the company's website.

Alkem Laboratories Ltd has announced the appointment of Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as Senior Management Personnels. The appointments are effective from October 12, 2026. Mr. Tiwari brings over 27 years of experience in pharmaceutical operations, holding an MBA in Operations Management and a Bachelor's degree in Pharmacy. Mr. Vartak has over 24 years of experience in supply chain leadership across pharmaceutical/healthcare and consumer goods sectors, with an MBA in Finance and a Bachelor's degree in Marine Engineering. Their detailed profiles and terms of appointment are provided as per SEBI LODR Regulations.

Alkem Laboratories Ltd has announced the closure of its trading window for insiders. The trading window will remain closed from September 29, 2026, until 48 hours after the company's financial results for the quarter and half-year ended September 30, 2026, are communicated to the stock exchanges. This action is in compliance with the company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders.

Alkem Laboratories Ltd. has issued a corporate guarantee of Euro 54.45 Million to HSBC UK Bank plc. This guarantee supports a term loan of Euro 49.5 Million availed by M/s. Occlutech Holding AG, a step-down subsidiary of Alkem located in Switzerland. The company confirmed that the transaction is at arm’s length and that the promoter/promoter group/group companies have no interest in this transaction. This corporate guarantee creates a contingent liability for Alkem Laboratories, meaning the company would be responsible for the debt if Occlutech defaults on its loan.

Alkem Laboratories Limited has announced the launch of NeuCeno (cenobamate), an anti-seizure medication (ASM) for adult patients suffering from partial-onset seizures. This marks the first time cenobamate is being introduced in India. NeuCeno is a once-daily oral therapy available in multiple dosage strengths. The drug targets epilepsy, a condition affecting an estimated 9.4 million people in India, with a unique dual mechanism of action. Clinical studies showed significant reductions in seizure frequency. The launch underscores Alkem's commitment to providing advanced and affordable treatment options to address unmet medical needs in epilepsy management.

Alkem Laboratories Ltd has announced the appointment of Dr. Shubhadeep Sinha to a senior management position within the company. The appointment is effective from September 15, 2026. Dr. Sinha brings over 25 years of experience in clinical development, medical affairs, pharmacovigilance, regulatory affairs, and healthcare management. This appointment is in compliance with SEBI LODR Regulations, and further details are available on the company's website. The company has confirmed no disclosure of relationships between directors is applicable.

Alkem Laboratories Ltd. has launched Renocia Exo™, India's first patented Ginsenoside Exosome-based hair growth serum. This next-generation therapy aims to support hair follicle health and vitality through a comprehensive scientific approach. The formulation integrates Ginsenoside phyto-exosomes, biomimetic peptides, copper peptides, and stem cell-supportive actives. It addresses hair loss, a growing dermatological concern in India, by supporting multiple biological processes associated with healthy hair follicle function, rather than just stimulating visible growth. The product is free from alcohol, sulphates, silicones, parabens, and mineral oil, making it suitable for regular use. This launch strengthens Alkem's dermatology portfolio by translating scientific insights into therapeutic innovations.

HDFC Mutual Fund has disclosed its aggregate holdings in Alkem Laboratories Limited, reaching 5.017% of the company's paid-up equity share capital as of August 24, 2026. This disclosure is made in accordance with Regulation 29(1) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing details the various schemes under HDFC Mutual Fund that contribute to this holding, acquired through open market transactions. The total paid-up equity share capital of Alkem Laboratories is Rs. 23,91,30,000/-, comprising 11,95,65,000 equity shares of Rs. 2/- each.

Alkem Laboratories Ltd has announced the opening of its trading window effective August 17, 2026. This follows the communication of the company's financial results for the quarter ended June 30, 2026, to the stock exchanges on August 14, 2026. The trading window had been closed from June 29, 2026, in accordance with the company's policy regarding financial results disclosure. The company has formally informed the exchanges about the conclusion of this blackout period.

Alkem Laboratories Ltd announced that its Board of Directors has approved the establishment of a new manufacturing block at its existing facility in Baddi, Himachal Pradesh. The company plans to invest up to INR 75 crores for this expansion. This move is expected to enhance Alkem's manufacturing capabilities and support its future growth strategies. Further details will be available on the company's website.